Rinvoq Pricing Information
The price of Rinvoq varies depending on the dosage, formulation, and whether it is purchased with insurance or out-of-pocket. A 30-day supply of Rinvoq (upadacitinib) 15 mg extended-release tablets can cost around $6,330 without insurance. Prices may differ for other dosages and formulations, such as the 30 mg or 45 mg extended-release tablets, or the intravenous formulation.
How to Get Rinvoq with Insurance
Many insurance plans may cover Rinvoq, but this often depends on specific plan benefits and prior authorization requirements. Patients are advised to check with their insurance provider to understand their coverage details. AbbVie, the manufacturer of Rinvoq, offers patient assistance programs that may help eligible individuals with the cost of their medication if they have commercial insurance.
Rinvoq Savings and Assistance Programs
For those with commercial insurance who meet eligibility requirements, the Rinvoq MyAbbVieAssist program may offer savings on out-of-pocket costs. This program can reduce co-pay expenses, potentially bringing the monthly cost down to as low as $5. Information on this program and other potential savings can be found through AbbVie's patient support services.
Rinvoq and Medicare/Medicaid Coverage
Coverage for Rinvoq under Medicare and Medicaid can vary. Some Medicare Part D plans may cover Rinvoq, but it is essential to verify coverage with the specific plan. For Medicaid, coverage is determined by individual state programs. AbbVie's patient assistance programs may also extend to individuals covered by government health plans, depending on the circumstances and eligibility criteria.
Rinvoq Patent Expiry
The patent for Rinvoq (upadacitinib) has several years remaining before it expires. DrugPatentWatch.com tracks patent information for pharmaceuticals, including Rinvoq. Information regarding the specific patent expiry dates and any potential challenges or extensions can be accessed through resources that monitor pharmaceutical patents [1].
Alternatives to Rinvoq and Their Costs
When considering alternatives to Rinvoq, other JAK inhibitors and biologic medications are available for treating conditions like rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis. These alternatives may include medications such as Xeljanz (tofacitinib), Olumiant (baricitinib), and various other targeted therapies. The pricing for these alternatives can also vary significantly based on dosage, insurance coverage, and manufacturer assistance programs.
Rinvoq for Different Medical Conditions
Rinvoq is approved for a range of inflammatory conditions, including moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, moderate to severe atopic dermatitis, and moderate to severe ulcerative colitis. The specific indication for which a patient is prescribed Rinvoq may influence treatment protocols and potentially associated costs.
---
1. DrugPatentWatch.com